Why Suicide Risk Screening Received an Insufficient Evidence Statement

In June 2023, the U.S. Preventive Services Task Force (USPSTF) published its recommendation on screening for depression and suicide risk in adults and gave universal suicide-risk screening an I statement. An I statement means the Task Force concluded that the current evidence is insufficient to assess the balance of benefits and harms. It is not a finding that screening is useless or dangerous. The research needed to answer the question, whether the screening tools accurately identify who is at risk, and whether acting on the results improves outcomes, simply was not there in adequate quantity or quality. That distinction, between a gap in evidence and evidence of no benefit, is the whole story here.

What an I statement actually says

The USPSTF grades a preventive service on a five-level scale. A and B mean the service is recommended because the net benefit is at least moderate with reasonable certainty. C means offer it selectively. D means recommend against it, because there is moderate or high certainty that the service has no net benefit or that harms outweigh benefits. The I statement sits apart from all of these. In the Task Force's own words, it means "the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined."

The practical guidance attached to an I statement is telling. It does not say stop. It says that if the service is offered, patients should understand the uncertainty about the balance of benefits and harms. This is a statement about what we know, not a prohibition on what clinicians may do.

Why suicide-risk screening landed here

The 2023 recommendation, published in JAMA, applies to adults 19 years and older, including pregnant and postpartum persons and older adults, who do not already have a diagnosed mental health disorder. In the same document, depression screening in this population earned a B grade. Suicide-risk screening did not. The difference is instructive because it shows the grading system responding to the strength of the underlying evidence rather than to the seriousness of the condition.

The evidence review identified gaps at every link of the chain that would need to hold for screening to demonstrably help:

Accuracy of the tools

To screen usefully, you need an instrument that reliably separates people at elevated risk from those who are not. For depression, tools such as the PHQ-9 have well-characterized performance. For suicide risk in the general adult population, the Task Force found inadequate evidence about the accuracy of the screening instruments. Without knowing how well a tool identifies risk, you cannot estimate how many people it would correctly flag or falsely reassure.

Benefits of screening

Even an accurate tool only helps if screening asymptomatic adults, then acting on the results, changes outcomes. The review found inadequate evidence on whether screening for suicide risk improves health outcomes, and inadequate evidence on the effectiveness of the treatments that would follow a positive screen in this specific screening context.

Harms of screening

The balance also requires understanding potential harms, including the consequences of false positives and the burden of downstream interventions. Here too, the Task Force found the evidence inadequate to assess potential harms.

When three of the pillars needed to weigh benefit against harm are each described as inadequate, the honest conclusion is that the balance cannot be determined. That is what the I statement records.

Insufficient evidence is not evidence of no benefit

This is the point most often lost in translation. A D grade and an I statement can both leave a service unrecommended in a strict screening sense, but they rest on opposite epistemic footing.

A D grade is a positive finding: the Task Force has moderate or high certainty that the service does not help or that its harms outweigh its benefits. Something is known, and what is known argues against the service.

An I statement is the absence of a finding: the studies that would let anyone reach a confident conclusion have not been done, or were too small, too inconsistent, or too methodologically weak to trust. The question remains open. To read an I statement as a verdict against a service is to convert missing data into a negative result, which is a logical error with real consequences. It can discourage the very research that would resolve the uncertainty, and it can be misused to argue that a clinical practice has been rejected when it has only been unstudied.

The reverse error matters too. An I statement is not permission to assume benefit. It is a neutral acknowledgment that we do not yet know, which is why the associated guidance emphasizes informed uncertainty rather than routine adoption.

How to read a recommendation like this

When a respected body issues an insufficient-evidence rating, the useful questions are diagnostic. Which specific links in the causal chain were unsupported, accuracy, benefit, or harm? Was the evidence missing, or present but conflicting? Does the rating apply to everyone, or to a defined population, in this case adults without an existing mental health diagnosis, which is different from patients already in care where risk assessment follows other logic?

Reading the recommendation this way turns a one-letter grade back into what it was meant to be: a map of what is known and, just as importantly, what is not. The suicide-risk I statement is best understood as a research agenda. It marks the boundary of current knowledge and points to the studies, on tool accuracy, on screening benefit, on harms, that would let a future Task Force reach a firmer conclusion in either direction.

This article is educational and is not medical advice. Anyone concerned about suicide risk for themselves or another person should seek help from a qualified professional or an appropriate crisis service.